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Abstract
We have previously shown that the eye is a mineralocorticoid-sensitive organ and we now question the role of
mineralocorticoid receptor (MR) in ocular inflammation. The endotoxin-induced uveitis (EIU), a rat model of human
intraocular inflammation, was induced by systemic administration of lipopolysaccharide (LPS). Evaluations were made 6 and
24 hours after intraocular injection of aldosterone (simultaneous to LPS injection). Three hours after onset of EIU, the MR
and the glucocorticoid metabolizing enzyme 11-beta hydroxysteroid dehydrogenase type 2 (11b-HSD2) expression were
down-regulated in iris/ciliary body and the corticosterone concentration was increased in aqueous humor, altering the
normal MR/glucocorticoid receptor (GR) balance. At 24 hours, the GR expression was also decreased. In EIU, aldosterone
reduced the intensity of clinical inflammation in a dose-dependent manner. The clinical benefit of aldosterone was
abrogated in the presence of the MR antagonist (RU26752) and only partially with the GR antagonist (RU38486).
Aldosterone reduced the release of inflammatory mediators (6 and 24 hours: TNF-a, IFN-c, MIP-1a) in aqueous humor and
the number of activated microglia/macrophages. Aldosterone partly prevented the uveitis-induced MR down-regulation.
These results suggest that MR expression and activation in iris/ciliary body could protect the ocular structures against
damages induced by EIU.
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Introduction
The aldosterone/mineralocorticoid receptor (MR) pathway is
known for its role in extracellular volume and blood pressure
regulation through the renal sodium absorption and potassium
excretion in the distal nephron epithelium. Aldosterone binds to
the mineralocorticoid receptor (MR), a transcription factor of the
steroid receptor superfamily that also includes the glucocorticoid
receptor (GR) [1,2]. The MR binds aldosterone and glucocorti-
coids with similar high affinity. Glucocorticoids largely prevail in
the plasma. Permanent MR occupancy by glucocorticoids is
prevented by the metabolizing enzyme 11-beta hydroxysteroid
dehydrogenase type 2 (11b-HSD2), which transforms the
glucocorticoids (cortisol in humans, corticosterone in rodents) into
metabolites that have a weak affinity for the MR [1,2].
Mineralocorticoid specific effects require co-expression of MR
and 11b-HSD2 like in the distal nephron. Beside this classical role
in the kidney, the aldosterone/MR pathway was discovered to
exert regulatory functions in non-epithelial cells including neurons,
adipocytes, cardiomyocytes and in vascular cells [1,2]. Patholog-
ical MR activation has been evidenced in cardiovascular diseases
[3]. Indeed, its antagonism by anti-mineralocorticoid drugs
(spironolactone, eplerenone) has proven to be mostly beneficial
to limit morbidity and mortality in heart failure and myocardial
infarction [4,5]. Pathological chronic MR activation is suspected
to induce tissue damages at least in part through inflammation [6].
In myeloid cells, MR activation was shown to favor M1
macrophages polarization whilst MR abrogation induced M2
polarization and subsequent cardiovascular tissue protection [7].
In the brain, acute post-ischemic damages were also reduced in
myeloid-MR deficient mice [8]. Moreover, in patients with
diabetic nephropathy, MR blockade reduced inflammation
markers [9,10]. Aldosterone increased the expression of vascular
cell adhesion molecule-1 in aortic endothelial cells [11] and
stimulated a pro-inflammatory phenotype in other non-inflamma-
tory cells such as adipocytes [12] and smooth muscle cells [13]
reinforcing the idea that MR pathway activation in both resident
and inflammatory cells stimulates inflammation, contributing to
subsequent tissue damage.
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We have recently shown that retinal cells and choroidal
endothelial cells express MR and 11b-HSD2, identifying the
retina and the choroid as mineralocorticoid-sensitive tissues
[14,15]. The MR and the 11b-HSD2 are also expressed in the
iris and ciliary body [16,17], which are part of uveal tract, the mid-
layer of the eye (Fig. S1). These tissues are targets of ocular
inflammation called uveitis. In humans, intraocular inflammation
can be idiopathic or part of systemic inflammatory diseases such as
spondyloarthritis or Behc¸et’s disease [18]. Uveitis is responsible for
about 10% of the cases of severe visual handicap [18]. In the eye,
blood-ocular barriers contribute to protect ocular tissues from
inflammatory cells invasion and subsequent tissue damages [19].
Blood-aqueous barrier is formed by tight-junctions between
endothelial cells of the iris and between epithelial cells of the
ciliary body [20]. Uveitis is associated with ocular barrier
breakdown through mechanisms that are not fully understood.
The endotoxin-induced uveitis (EIU) is a well-characterized rat
model for human acute uveitis [21]. Resident cells (microglial cells,
iris/ciliary body endothelial and epithelial cells) are activated early
and produce cytokines, chemokines and iNOS (inducible nitric
oxide synthase) about 4 hours after LPS injection [22]. Later (8
hours), circulating inflammatory cells (polymorphonuclear leuko-
cytes and macrophages) invade the anterior segment tissues of the
eye [22,23,24].
The implication of aldosterone/MR pathway activation in
ocular inflammation has never been questioned. Our aim was to
evaluate the impact of MR pathway activation or inhibition on




Animal experiments were approved by the Institutional Animal
Care and Use Committee: «Comite´ d’e´thique en expe´rimentation
animale Charles Darwin» (ID Ce5/2009/029), INSERM U289,
Hoˆpital Salpe´trie`re, Paris and performed in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Adult female Lewis rats (6–8 weeks old; Janvier,
Le Genest-Saint-Isle, France) were used (number of animals (n) are
indicated in Fig. legends). Anesthesia of rats was induced by
intraperitoneal injection of pentobarbital (25 mg/kg Nembutal;
Abbot, Saint-Remy sur Avre, France). One drop of 1% tetracaine
(Sigma-Aldrich, Saint Quentin Fallavier, France) was instilled for
local eye anesthesia before intravitreal injection. Rats were
sacrificed by a lethal dose of pentobarbital intraperitoneal
injection. After sacrifice, the eye was removed, either processed
for morphology or dissection to collect aqueous humor and iris/
ciliary body.
Induction of EIU
EIU was induced in rats by a single footpad injection of 100 ml
sterile pyrogen-free saline containing 200 mg lipopolysaccharide
(LPS) from Salmonella typhimurium (Sigma-Aldrich) as previously
described [25].
Acute anterior segment inflammation of the eye reaches its
maximum intensity at 24 hours, then spontaneous resolves in 7
days [21,22].
Aldosterone and Spironolactone Injections into the
Vitreous Body of the Rat Eye
Aldosterone or MR antagonist (spironolactone, RU26752) or
GR antagonist (RU38486) or solvents (NaCl 0.9% with 0.1%
ethanol) were injected into the vitreous body of both eyes
(intravitreal injections: IVT) as previously described [15]
simultaneously to LPS injection. We injected 5ml (i.e. 10% of
the vitreous volume) of aldosterone (1 nM, 20 nM or 200 nM
final concentrations) or spironolactone (10 mM), or MR
antagonist RU26752 (10 mM), or GR antagonist RU38486
(10 mM), or aldosterone (200 nM) associated with the MR
antagonist RU26752 (20 mM), or aldosterone (200 nM) associ-
ated with the GR antagonist RU38486 (20 mM). Drugs were
purchased from Sigma-Aldrich.
Clinical Examination
The inflammation was scored 24 hours after LPS challenge and
intravitreal injection using biomicroscopy analysis as previously
described [25]: grade 0: no inflammation; grade 1, minimal iris
and conjunctival vasodilation but without cells in the anterior
chamber; grade 2, moderate iris and conjunctival vessel dilation
but without evident cells in the anterior chamber; grade 3, intense
iris vessels dilation and fewer than 10 cells per slit lamp field in the
anterior chamber; grade 4, more severe clinical signs than grade 3,
with more than 10 cells in the anterior chamber with or without
the formation of hypopyon (ie: accumulation of inflammatory cells
in the anterior chamber); grade 5, intense inflammatory reaction,
fibrin formation in the anterior chamber, and total seclusion of the
pupil (ie: pupil that does not react to light due to fibrin clot).
Scoring was performed by a masked investigator.
Cytokine and Chemokine Analysis in Aqueous Humor
Multiplex ELISA assay (Milliplex Map Kit, Millipore, Saint-
Quentin en Yvelines, France), was performed on rat aqueous
humor at 6 and 24 hours after LPS injection according to the
manufacturer’s instructions. The following inflammatory media-
tors were measured: interleukin-1beta (IL-1b), IL-2, IL-4, IL-5, IL-
6, IL-10, IL-13, IL-17, IL-18, tumor necrosis factor-alpha (TNF-
a), interferon-gamma (IFN-c), vascular endothelial growth factor
(VEGF); chemokines: monocyte chemotactic protein-1 (MCP-1),
macrophage inflammatory protein-1alpha (MIP-1a), regulated
upon activation normal T cell expressed and secreted (RANTES),
interferon-inducible protein-10 (IP-10), growth related oncogene
(GRO/KC). Detection thresholds of the kits were 1 to 10 pg/ml.
Immunofluorescence
Eyes were snap frozen in Tissue-Tek OCT-compound (Bayer
Diagnostics, Puteaux, France). Cryostat sections (10 mm) were
incubated with primary antibodies, further incubated with the
corresponding secondary antibodies (Invitrogen, Cergy-Pontoise,
France) and stained with 49, 6-Diamidino-2-Phenyl-Indole (DAPI,
1:3000, Sigma-Aldrich). Control sections were stained without
primary antibodies. Images were taken using a fluorescence
microscope (Olympus BX51, Rungis, France) equipped with
a CCD camera (Olympus DP70). The following primary
antibodies were used: mouse monoclonal anti-iNOS (dilution
1:75, Santa Cruz Biotechnology, CA, USA), rabbit polyclonal
anti-ionized calcium binding adaptor molecule-1 (anti-IBA-1;
dilution 1:400, Wako, Richmond, USA) a specific marker for
microglia/macrophages [26].
Quantification of Activated IBA-1 Stained Cells
To quantify ocular cell infiltration/activation and the effect of
aldosterone or spironolactone treatment on ocular inflammation,
all round activated IBA-1 stained cells were counted on entire
ocular cross sections (2 sections per eye) at the optic nerve level, as
previously described [25].
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MR and GR Immunohistochemistry
GR and MR were evaluated at 24 hours after LPS injection by
immunohistochemistry on eye paraffin sections as previously
described [14]. Negative controls were performed without primary
antibodies. The following antibodies were used: mouse mono-
clonal anti-MR 6G1 (1:100, kindly provided by C. Gomez-
Sanchez, Division of Endocrinology, University of Mississippi
Medical Center, Jackson, MS), rabbit anti-GR (1:2000, Santa
Cruz, Heidelberg, Germany), biotinylated horse anti-mouse IgG
BA2000 (1:250, Vector) and biotinylated goat anti-rabbit IgG
BA1000 (1:500, Vector).
Reverse Transcription and Real-time PCR
Total RNA was isolated from iris/ciliary body using RNeasy
plus Mini Kit (Qiagen, Courtaboeuf, France) for real-time PCR
analysis of MR, GR, 11b-HSD1 and 11b-HSD2 expression as
previously described [14]. RNA was also extracted from cells
collected in the aqueous humor at 24 hours to quantify iNOS
expression in infiltrating cells. The 18S was used as internal
control. Table 1 shows sequences of primers.
Corticosterone ELISA
A corticosterone acetylcholinesterase competitive EIA assay
(Cayman, MI, USA) was performed on rat aqueous humor
according to the manufacturer’s instructions. Absorbance was
measured with a multi-well plate reader (Benchmark Plus
Microplate Spectrophotometer System, Bio-Rad Laboratories,
California, USA).
Statistics
Data were expressed as means 6 SEM. n is the number of rats.
Statistical analysis was made using the Graphpad Prism5 program
(Graphpad Software, San Diego, CA, USA). Clinical scoring was
analyzed using the non-parametric Kruskal Wallis test followed by
Dunn’s multiple comparison test. Other data were analyzed with
one-way ANOVA test followed by Bonferroni’s comparison.
P,0.05 deemed significant.
Results
Down-regulation of MR and 11b-HSD2 Expression in Iris/
ciliary Body During Uveitis
Real-time PCR analyses show that MR mRNA is expressed in
rat iris/ciliary body (Fig. 1A, without LPS). As early as 3 hours
after LPS injection, a major down-regulation of MR expression
was observed, that was sustained at 6 and 24 hours (Fig. 1A).
Reduction in MR levels was specific for this receptor, as the closely
related glucocorticoid receptor (GR) transcripts levels were not
altered in the early phase of EIU (3 and 6 hours); down-regulation
of GR mRNA was observed only 24 hours after onset of EIU
(Fig. 1B). Immunolocalization experiments extended these ob-
servations at the protein level (Fig. 1C). The MR and the GR are
expressed in the iris epithelial and endothelial cell nuclei and
probably in other resident cells of the iris stroma (Fig. 1C, without
LPS). Twenty-four hours after LPS injection, MR and GR were
down-regulated (Fig. 1C, 24 h LPS). The lower GR staining may
be due to swollen tissues, in addition to the lower expression of GR
inferred from the low GR transcript levels at 24 hours.
Down-regulation of transcripts encoding for the glucocorticoid-
inactivating enzyme 11b-HSD2 (corticosterone to 11dehydrocor-
ticosterone in rats) was parallel to the down-regulation of the MR
(Fig. 1D); corticosterone concentration in aqueous humor was
enhanced 3 and 6 hours after LPS injection (Fig. 1E). In contrast,
the mRNA levels of enzyme 11b-HSD1 driving the opposite
reaction (11dehydrocorticosterone to corticosterone) were higher
24 hours after LPS challenge (Fig. 1F).
These results led us to question the role of the MR in uveitis.
MR Activation Limits the Severity of Uveitis
Clinically, uveitis is characterized by vasodilation of the iris
vessels, infiltration of inflammatory cells in the eye and proteins in
aqueous humor that witness rupture of ocular barriers. Clinical
scoring was performed at 24 hours, the peak of inflammation in
our model [25]. Aldosterone, injected in the eyes concomitant to
LPS challenge, induced a significant and dose-dependent re-
duction of the clinical intensity of EIU as compared to vehicle-
injected rats (Fig. 2A); maximal protective effect of aldosterone was
observed at 20–200 nM. Aldosterone improvement of ocular
inflammation was suppressed when the hormone was co-injected
with the MR antagonist RU26752, indicating that the anti-
inflammatory protecting effect of aldosterone is MR-mediated
(Fig. 2B). At this concentration, aldosterone may also activate the
GR as inferred from the intermediate clinical score obtained by
aldosterone associated with the GR antagonist RU38486 (Fig. 2B).
None of these antagonists alone significantly modified the clinical
score of uveitis (mean 6 SEM: Vehicle: 3.660.2;
RU26752:4.060.1; RU38486:3.760.3; n= 5 rats per conditions).
In this pathological context, MR antagonism might be
deleterious. To test this hypothesis, we injected spironolactone
(10 mM) intravitreously, concomitantly with LPS injection in
footpad, to block (or limit) MR activation by endogenous ligands
(aldosterone or glucocorticoids) (Fig. 2A). However the MR
antagonist did not significantly increase the clinical severity of the
disease.
All further analyses were performed with aldosterone 200 nM
and spironolactone 10 mM.
Aldosterone-MR Activation Reduces Pro-inflammatory
Mediators
To assess the anti-inflammatory role of aldosterone in EIU, we
determined the effect of aldosterone injection on chemokines and
cytokines production in aqueous humor. In the early phase of EIU
Table 1. Real-time PCR primers.
Gene SYBR Green Primers (rat)
18S sense 59-AAG TCC CTG CCG TTT GTA CAC A-39
18S antisense 59-GAT CCG AGG GCC TCA CTA AAC-39
GR sense 59-AAC ATG TTA GGT GGG CGT CAA-39
GR antisense 59-GGT GTA AGT TTC TCA AGC CTA GTA TCG-39
MR sense 59-GGC TAC CAC AGT CTC CCT GA-39
MR antisense 59-ACG TTG ACA ATC TCC ATG TAG-39
11b-HSD1 sense 59-GAA GAA GCA TGG AGG TCA AC-39
11b-HSD1 antisense 59-GCA ATC AGA GGT TGG GTC AT-39
11b-HSD2 sense 59-TGC TGG CTG GAT CGC GTT GTC-39
11b-HSD2 antisense 59-CAC AGT GGC CAG CAC GGT GAA-39
iNOS sense 59-CTC GGA GGT CCA CCT CAC TGT-39
iNOS antisense 59-GGT TAT TGA TCC AAG TGC TGC-39
doi:10.1371/journal.pone.0049036.t001
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(i.e. 6 hours), aldosterone significantly decreased several pro-
inflammatory mediators: TNF-a, IFN-c, IL-2, MCP-1, MIP-1a as
compared to vehicle injection while IL-6 levels were not modified
(Fig. 3A). At 24 hours the aldosterone-induced reduction of TNF-
a, IFN-c and MIP-1a was sustained (Fig. 3B). There was no
significant effect on other tested cytokines (IL-1b, IL-18, IL-4, IL-
Figure 1. MR, GR, 11b-HSD1, 11b-HSD2 expression in iris/ciliary body and corticosterone concentration in aqueous humor during
EIU. A–B: Time-course of MR (A) and GR (B) mRNA expression (real-time PCR). After LPS injection, down-regulation of GR was observed only at 24
hours, whilst MR expression was down-regulated already at 3 hours. The 18S was used as housekeeping gene. Results in EIU are relative to those
without LPS injection. Data are means 6 SEM; n = 6 rats per conditions; **p,0.01, ***p,0.001. C: Immunohistochemistry of MR and GR in iris
sections. In normal iris rat, MR and GR are localized in the nuclei of the iris epithelial cells (arrow), endothelial cells (arrowhead) and probably in other
resident cells of the iris stroma. Twenty-four hours after LPS injection, MR and GR expression signals were reduced in uveitis eyes (star: vessels).
Negative controls are signals yielded in the absence of primary antibody. Scale bar = 40 mm; 20 mm for insert. D–F: Time-course of 11b-HSD2 (D), 11b-
HSD1 (F) expression (real-time PCR) and corticosterone concentration in aqueous humor (E). LPS injection induced an early (3 hours) down-regulation
of 11b-HSD2 transcripts and a late up-regulation of 11b-HSD1 transcripts at 24 hours compared to rats without LPS injection. The 18S was used as
housekeeping gene. Results in EIU are relative to those without LPS injection. Corticosterone concentration in aqueous humor increases at 3 and 6
hours after LPS injection. Data are means 6 SEM; n = 6 rats per conditions; *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0049036.g001
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5, IL-10, IL-13, IL-17) or chemokines (RANTES, IP-10, GRO-
KC) (data not shown). In contrast, intravitreal injection of
spironolactone led to a significant increase in IL-6 at 6 hours
(Fig. 3A) and a significant increase in TNF-a, IFN-c, IL-6, IL-2
and MCP-1 at 24 hours (Fig. 3B).
It can be noticed that cytokines/chemokines concentrations
were higher at 6 hours than at 24 hours, consistent with previous
studies showing a peak of pro-inflammatory cytokines about 3–6
hours after LPS injection [27,28].
These results show that MR activation by aldosterone exerts
anti-inflammatory effects in EIU through early reduction of pro-
inflammatory cytokines in ocular fluids. Of interest, these
variations occurred at a time when circulating inflammatory cells
have not yet penetrated into the eye and thus could correspond to
the secretion of cytokines by ocular activated resident cells.
Aldosterone/MR Influences Microglia Activation
To evaluate the effect of aldosterone on microglia activation
and macrophages recruitment, we used the anti-ionized calcium
binding adaptor molecule 1 (IBA-1) on cryostat sections. Round-
shaped IBA-1 positive cells represent activated cells while ramified
ones are resting cells. In aldosterone-injected eyes, most microglial
cells in iris/ciliary body showed a resting ramified shape with
ramifications as compared to round-shaped IBA-1 positive cells in
vehicle or spironolactone-injected eyes (Fig. 4A). The number of
round activated IBA-1 positive cells was significantly decreased in
aldosterone-injected eyes as compared to vehicle or spironolac-
tone-injected ones (Fig. 4B). Co-labeling of IBA-1-positive cells
with iNOS showed that iNOS was not expressed by microglia in
aldosterone-treated eyes, whilst few round microglia expressed
iNOS in spironolactone or vehicle-treated eyes (Fig. 4C). Further,
in infiltrating cells collected from aqueous humor of eyes with
uveitis, iNOS mRNA expression was significantly reduced by
aldosterone, compared to vehicle (Fig. 4D). This effect was
prevented by the co-administration of aldosterone plus RU26752
(MR antagonist) (Fig. 4D), demonstrating the anti-inflammatory
role of MR pathway.
In EIU, Aldosterone Restores MR Expression in Iris/ciliary
Body
Aldosterone IVT restored (at least partially) the MR expression
that had been reduced by LPS during EIU (Fig. 1): improvement
was evidenced 6 hours after onset of EIU (an increment that was
sustained at 24 hours) (Fig. 5A, B). GR expression was also
increased after aldosterone IVT injection at 6 hours and 24 hours
(Fig. 5C, D). On the opposite, intravitreal injection of spirono-
lactone decreased MR transcripts compared to vehicle-injected
rats at 24 hours (Fig. 5B) and had no effect at 6 hours (Fig. 5A).
Discussion
In humans as well as in animal models, long-term inappropriate
or excessive MR activation, due to chronic ligand increase
(aldosterone or glucocorticoids) or receptor overexpression and/
or activity, was found to promote inflammation and oxidative
stress markers in kidney and cardiovascular pathologies [29]. Of
note, deleterious effects of aldosterone require association of MR
activation to a pathological context or to additional stress, such as
high sodium diet and uninephrectomy. Of major clinical
relevance, it was demonstrated that MR antagonism limits the
progression of cardiovascular end-organ damage [4,5].
The retina and the choroid are now emerging as novel
mineralocorticoid-sensitive tissues, as the MR pathway has
recently been evidenced in normal and diseased eye [14,15,30].
We previously showed that the retina is a mineralocorticoid target
and that the MR pathway regulates ion and water channels
expression in Mu¨ller glial cells, contributing to the fluid
homeostasis of the retina [14]. We also demonstrated that MR
pathway controls choroidal vascular bed relaxation and is involved
in the pathogenesis of central serous chorioretinopathy, a human
ocular disease [15]. The group of Wilkinson-Berka identified MR
involvement in retinal vascular pathology in a rat model of
oxygen-induced retinopathy [30], as aldosterone favored patho-
logical angiogenesis of retinal vessels and participated to retinal
inflammation in this model.
Figure 2. Effects of intravitreal injection of aldosterone or spironolactone on clinical EIU. Clinical scores of the severity of EIU were
determined 24 hours after induction of EIU. Steroids were injected IVT in each eye, simultaneously to footpad LPS injection; 24 hours later, both eyes
were evaluated, and scores of each eye were gathered as the clinical score of the animal. A: Intravitreal injection (IVT) of aldosterone (aldo; 1, 20 or
200 nM) or spironolactone (spiro; 10 mm): aldosterone (20–200 nM) induced a significant reduction of the clinical severity of EIU, compared to vehicle
(Veh) IVT. Spironolactone did not modify the severity of EIU. Data are mean 6 SEM; n = 8 rats per condition. B: Intravitreal injection of aldosterone
(200 nM) alone or associated with the MR antagonist RU26752 (20 mM) or with the GR antagonist RU38486 (20 mM): benefit of aldosterone injection
was confirmed, which was blunted in the presence of RU26752. There was no statistical difference between aldosterone+RU38486 IVT and vehicle
injection or aldosterone IVT. Data are mean 6 SEM; n = 10 rats per condition; *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0049036.g002
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Figure 3. Cytokine/chemokine concentrations in aqueous humor. Cytokine/chemokine concentrations in aqueous humor were measured by
multiplex ELISA 6 or 24 hours after LPS injection associated to vehicle (Veh) or aldosterone (Aldo) or spironolactone (Spiro) intravitreal injection. A: At
6 hours, TNF-a, IFN-c, IL-2, MCP-1, and MIP-1a concentrations were significantly reduced in inflamed eyes with injection of aldosterone, compared to
vehicle-injected inflamed eyes; spironolactone enhanced IL-6 concentrations in rats with EIU. Data are mean 6 SEM; n = 5 rats per condition. B: At 24
hours, Aldosterone significantly reduced TNF-a, IFN-c and MIP-1a concentrations; spironolactone increased TNF-a, IFN-c, IL-6, IL-2 and MCP-1
concentrations. Data are mean 6 SEM; n = 8 rats per condition. *p,0.05.
doi:10.1371/journal.pone.0049036.g003
Figure 4. Aldosterone reduces activation of microglia/macrophages in EIU. A: Immunofluorescence detection of IBA-1 microglia/
macrophages on sections of inflamed eyes injected with vehicle, aldosterone or spironolactone. Twenty-four hours after LPS injection, in vehicle and
spironolactone-injected eyes, many microglial cells had a round amoeboid shape attesting for their activation in the iris/ciliary body. By contrast, in
aldosterone-injected eyes, more microglial cells had a resting dendritic shape with long branchings (white arrowheads). Merge images of IBA-1
(green) and DAPI (blue); scale bar: ciliary body: 40 mm; 25 mm for insert; iris: 60 mm. B: Quantification of activated IBA-1 microglia/macrophages on
sections of inflamed eyes that were injected with vehicle, aldosterone or spironolactone. Twenty-four hours after LPS injection, less number of round
activated IBA-1 positive cells was found in eyes sections with injection of aldosterone (Aldo) vs vehicle (Veh) or spironolactone (Spiro). Data are
expressed as means 6 SEM of 2 sections/rat; n = 4 rats per condition; *p,0.05, **p,0.01. C: Immunofluorescence of iNOS on sections of inflamed
eyes injected with vehicle, aldosterone or spironolactone. Twenty-four hours after LPS injection, few round IBA-1 positive macrophages/microglia
expressed iNOS in vehicle and spironolactone-injected eyes (colocalization: yellow, arrow). By contrast, iNOS signal was reduced in IBA-1 positive
macrophages/microglia in aldosterone-treated eyes. Merge image of IBA-1 (green), iNOS (red) and DAPI (blue); scale bar: 10 mm; n= 4 rats per
condition. D: iNOS mRNA expression (real-time PCR) in cells infiltrating the aqueous humor in EIU. In EIU, inflammatory cells (neutrophils and
macrophages) accumulate in aqueous humor. In cells collected in aqueous humor from EIU eyes, iNOS mRNA expression was significantly reduced by
aldosterone (Aldo) IVT compared to vehicle (Veh) IVT. This effect was prevented by the co-administration of aldosterone with the MR antagonist
RU26752. The 18S was used as housekeeping gene. Results are relative changes compared to vehicle-injected eyes. Data are means 6 SEM; n = 4–5
rats per condition; *p,0.05.
doi:10.1371/journal.pone.0049036.g004
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The MR may also be active in the anterior segment of the eye,
in particular in the iris and ciliary body. Its expression has been
documented in several species: GR, MR and 11b-HSD1 and 2
have been found in the ciliary body epithelium of the rabbit eye
[17]; MR and 11b-HSD2 are highly expressed in the ciliary body
epithelium of the rat and human eye [16]. Here we document MR
expression in the iris of rat eye. MR is therefore found in all cells
that constitute the blood-aqueous barrier, raising the question of
its role in an acute inflammatory state, such as uveitis.
In EIU, a rat model of uveitis, LPS activates macrophage/
microglia [23,31]. Both infiltrating and resident ocular cells
produce cytokines and iNOS. While iNOS mRNA was not
detected in the control eye (without LPS injection), it increased
from 2 to 24 hours after LPS injection [32,33]. The local cytokines
may originate from resident activated cells or from systemic
production reaching the damaged eye [34]. TNF-a is the most
important cytokine in the pathogenesis of EIU. It has been shown
that the mRNA levels of TNF-a are enhanced in the eye, as early
as 3 hours after LPS injection [22]. Most cytokines involved in
EIU achieved peak mRNA level in iris/ciliary body about 3–6
hours after LPS injection [28]. Our findings are consistent with
these kinetics. The lower values of IFN-c found in our study at
24 h may depend on the half-life of the cytokine in aqueous humor
or on individual variations, as reported by De Vos et al [34].
In sharp contrast with the bulk of literature reports on chronic
deleterious effects of aldosterone, we found that relatively short-
term aldosterone administration is anti-inflammatory in the
inflamed eye, in the context of EIU, an acute ocular inflammation
model. Although clinical scoring is subjective, its improvement by
aldosterone is strengthened by convergent data including cytokine
profiles in ocular media, cells counts in ocular tissues, microglia
activation in the iris/ciliary body and iNOS expression in
inflammatory cells accumulating in aqueous humor.
Recent studies questioned the role of the MR in an infectious
context. In dog sepsis, specific MR agonists increased survival
when given preventively [35]. It was also observed that mortality
was enhanced by spironolactone during infectious colitis in two
rodents model and in humans [36]. In neutrophils, functional MR
was reported to mediate anti-inflammatory effects via inactivation
of nuclear factor-kappa B (NF-kB); indeed aldosterone strongly
diminished NF-kB dependant TNF-a production in IL-8 stimu-
Figure 5. MR and GR mRNA expression after intravitreal injection of aldosterone or spironolactone in the eye of LPS-injected rats.
EIU was associated to down-regulation of MR and GR (Fig. 1). A–B: MR expression in iris/ciliary body (real-time PCR): In the inflamed eye, intravitreal
injection of aldosterone (Aldo) increased MR transcripts at 6 hours (A) and 24 hours (B) in EIU vs vehicle-injected eyes (Veh). Intravitreal injection of
spironolactone (Spiro) decreased MR transcripts compared to vehicle-injected rats at 24 hours (B) and had no effect at 6 hours (A). C–D: GR
expression in iris/ciliary body (real-time PCR): In the inflamed eye, intravitreal injection of aldosterone increased GR transcripts at 6 hours (C) and 24
hours vs vehicle-injected eyes (D). GR expression was not statistically modified by spironolactone. The 18S was used as housekeeping gene. Results
are relative values of aldo/spiro relative to vehicle injection. Data are means 6 SEM; n = 5–7 rats per condition; *p,0.05.
doi:10.1371/journal.pone.0049036.g005
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lated neutrophils, resulting in reduced neutrophil adhesion to
endothelial cells [37].
MR activation may also be beneficial in non-infectious
situations. Cardiac aldosterone production was shown to prevent
the reduction in capillary density in diabetic mice [38]. Pro-
angiogenic effects of aldosterone were also inferred from improved
neovascularization following limb ischemia in mice [39]. Thus,
depending on the cellular and pathological context, aldosterone/
MR signaling may exert opposite effects, either deleterious or
beneficial.
While anti-inflammatory effects of glucocorticoids and GR
pathway have been largely documented, this study brings new data
demonstrating that the aldosterone/MR pathway exerts also anti-
inflammatory effects. The beneficial effect of aldosterone in uveitis
was observed at relatively high dose (200 nM) that may activate
both MR and GR. However, in vivo the exact dose that efficiently
reaches the iris/ciliary body after intravitreal injection cannot be
ensured. The fact that the co-injection of aldosterone with the MR
antagonist clearly prevents the anti-inflammatory effect of
aldosterone/MR pathway reinforces the idea that the MR
pathway is involved in the observed effect. Aldosterone may also
activate the GR as inferred from the intermediate clinical score
obtained by aldosterone plus RU38486 treatment. Indeed, the GR
also has comparable (but low) affinity for binding aldosterone and
glucocorticoids (12 nM); However the ED50 (Effective Dose 50) for
transactivation activity of the GR occupied by dexamethasone is
about 15 nM and 120 nM with aldosterone [40]. Moreover, MR
can form homodimers or heterodimers with the GR with distinct
transcriptional activity [41] and a series of downstream events also
influence mineralocorticoid selectivity (co-activators and tissue-
specific transcription factors, post-translational processing of the
MR [2,42]…) Any of these elements may be altered in pathology.
Very limited information is available yet on these pathophysio-
logical aspects.
The mechanism at the origin of the beneficial effect of
aldosterone in uveitis is currently unknown; we propose that it
may be related to its ability to prevent the uveitis-induced MR
down-regulation, at variance with situations where the MR is
inappropriately activated. In the early phase of uveitis (3 hours),
there is a series of changes that lead to less activation of MR and of
the opposite over-activation of the GR pathway; although GR
mRNA levels are unchanged, 11b-HSD2 mRNA is diminished,
a finding coherent with the rise in corticosterone in aqueous
humor. This result is consistent with the high cortisol levels
measured in aqueous humor of patients with uveitis [43].
Corticosterone in aqueous humor may originate from adrenal
production as the consequence of the stress induced by uveitis. It
may also be the result of the reduced local 11b-HSD2 activity.
Thus, at the early phase of uveitis, the MR/GR balance is
shifted towards GR activity. Aldosterone injection restores (at least
partially) MR signaling and prevents the MR/GR imbalance.
MR down-regulation was evidenced in vivo as early as 3 hours
after LPS injection, i.e. at a time when no cells have infiltrated the
eye tissues [22], showing that MR down-regulation is associated to
the onset of ocular inflammation. Interestingly, in human retinal
and choroidal endothelial cells stimulated by LPS, a transcriptomic
analysis had reported reduced MR expression [44]. Moreover, in
brain microglial cells, GR and MR are also down-regulated by
LPS in a time-dependent manner, with an earlier decrease in MR
than in GR, suggesting that MR/GR pathways are involved in the
immunosuppressive role of endogenous steroids in these cells [45].
We have no straightforward explanation for the aldosterone-
dependent down-regulation of MR and GR in EIU, and limited
literature data document such ligand- dependent regulation. One
can speculate that GR and MR expression may depend on
pathways that are activated during inflammation such as NFkB.
In conclusion, our results show that MR intervenes in the very
early events of EIU and that aldosterone is anti-inflammatory in
this pathological context. Different glucocorticoids with different
MR affinity may therefore exert differential effects in uveitis.
Future clinical studies should evaluate this possibility in humans.
Supporting Information
Figure S1 Eye drawing shows the uveal tract (red), the
middle layer of the eye, formed by the choroid, iris and
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